A new guideline is coming! The AGA Living Guideline: Pharmacological Management of Moderate-To-Severe Ulcerative Colitis will be published in December 2024.
This guideline is intended to support practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC). The guideline centers around 14 recommendations for positioning therapies with a patient-centered approach in mind.
AGA has classified this as a “living guideline” and an update to our 2020 guideline, given the rapid changes and growth happening in the field. This means that throughout the development process, individual recommendations were updated based on the availability of new evidence at the time.
As part of our guideline development process, we invite you to review this new guideline and share feedback during the public comment period.
Submit your comments by July 31, 2024.
Guideline documents for review
About the public comment period
AGA develops clinical practice guidelines using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, which provides a common, sensible and transparent approach to grading the quality of evidence and strength of recommendations, and uses the best practices outlined by the Institute of Medicine.
The public comment period is an integral part of AGA’s guideline development process. It allows AGA members and key stakeholders to review and comment on upcoming guidelines and their accompanying technical reviews.
Once an AGA guideline panel releases the drafts for public comment, identified stakeholders are alerted and submit their comments through an online survey. After the period ends, the guideline panel reviews and responds to the comments within two weeks. Revisions to the draft documents are at the discretion of the panel, but all comments will be considered and responses internally documented.
To see previously published guidelines, visit AGA’s clinical guidance library.
